- Home
- Providers
- Neurology
- Neurodegenerative Diseases
- Alzheimer’s Disease (AD)
查找地点
有关时间、上门服务和预约Over 6 million people in the US are living with Alzheimer disease (AD)1, and over 80 million adults between 50-70 years whose biggest health fear, other than cancer, is AD2.
We want to help them all.
Each of the Alzheimer’s biomarker tests are orderable individually
484390
An aid in the identification of Alzheimer's disease pathology by detecting the presence or absence of pTau-217, which has been shown in the literature to be a surrogate of amyloid pathology. Additionally, pTau-217 can be used for monitoring patients on newly approved anti-amyloid therapies
505725
Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of amyloid pathology for Alzheimer’s disease
484440
GFAP is a protein expressed mostly in astrocytes in the brain. In conjunction with markers of amyloid pathology, GFAP has been shown to be a predictor of Alzheimer’s disease
140555
NfL, in the context of Alzheimer’s disease, provides an indication of disease severity by measuring the current level of neurodegeneration
483745
This test detects and quantifies pTau-181 proteins in plasma, which has been demonstrated to be predictive in differentiating Alzheimer’s from other dementias
484400
This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology
Contact a Labcorp representative to learn more about how we can help meet your neurology testing needs